Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A versus atezolizumab with etoposide/platinum in first-line extensive-stage small cell lung cancer
NL-OMON53681Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab + pembrolizumab, atezolizumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started Jun 2022; status: recruiting.
02
Drugs
vibostolimab + pembrolizumabatezolizumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON53681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53681.